Amgen completed a $10 billion share buyback on March 5, rounding up around 52.1 million shares of its common stock for $192 apiece. The shares bought in the offer represent about 7.2 percent of total outstanding shares, the company said in a March 6 press release. The Thousand Oaks-based biotech giant announced its intent to…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
